IGCNYSE

IGC Pharma, Inc.

Healthcare·Neurology·Phase 2·Potomac, MD, United States
NeurologyMetabolic

IGC Pharma, Inc. (IGC): 7 pipeline candidates · ~1 mo cash runway · 1 clinical trial. Updated within the last hour.

6.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.3

1.2 months

Financial Health9.2

D/E 0.50 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for IGC Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$28.5M

Cash

$207K

Quarterly Burn

$1.2M

Runway

1.2 mo

Revenue

$317K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

35

Total value held

$1.3M

HolderSharesValue
vanguard capital management llc1,436,872$378K
geode capital management, llc1,043,384$274K
blackrock, inc.703,798$185K
renaissance technologies llc483,975$127K
vanguard fiduciary trust co415,888$109K
state street corp200,799$53K
susquehanna international group, llp122,595$32K
northern trust corp113,407$30K
lawood & co75,000$20K
goldman sachs group inc65,541$17K

Showing top 10 of 35 institutional holders of IGC Pharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·CEO: Mr. Ram Mukunda

Frequently asked questions

How many drug candidates are in IGC Pharma, Inc.'s pipeline?

IGC Pharma, Inc. (IGC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is IGC Pharma, Inc.'s lead drug candidate?

IGC Pharma, Inc.'s most advanced tracked candidate is igc-1a (Preclinical) for Metabolic disorders (e.g., type 2 diabetes, obesity).

What is IGC Pharma, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, IGC Pharma, Inc. has approximately 1.2 months of cash runway.

What is IGC Pharma, Inc.'s market capitalization?

IGC Pharma, Inc.'s market capitalization is approximately $28.5M.

Who is the CEO of IGC Pharma, Inc.?

Mr. Ram Mukunda is the chief executive officer of IGC Pharma, Inc. (IGC).

Get the full picture on IGC Pharma, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.